Clinical Trials Browser

Interventional × copanlisib × Lymphoid × Clear all

NCT03502733 2026-03-18

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1 Active not recruiting

Lymphoma, Neoplasm Metastasis

NCT05490771 2026-03-18

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Phase 2 Active not recruiting

35 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06400238 2026-03-18

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Phase 2 Active not recruiting

35 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Phase 2 Active not recruiting

33 enrolled 17 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT04572763 2026-01-07

Copanlisib Plus Venetoclax in R/R DLBCL

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03884998 2025-12-30

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02367040 2025-10-14

CHRONOS-3

Phase 3 Completed

458 enrolled 22 charts

Lymphoma, Non-Hodgkin

NCT04433182 2025-08-08

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

Lymphoma, Large B-Cell, Diffuse

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04939272 2025-05-01

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Mantle-Cell

NCT04750941 2025-03-04

Study of Copanlisib and Ketogenic Diet

Phase 2 Terminated

1 enrolled 9 charts

GynecologicLymphoid

Lymphoma, Follicular, Endometrial Neoplasms

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Phase 2 Completed

12 enrolled 13 charts

Lymphoma, Large B-Cell, Diffuse

NCT02626455 2024-12-11

CHRONOS-4

Phase 3 Terminated

551 enrolled 32 charts

Lymphoma, Non-Hodgkin

NCT04431635 2024-09-27

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Phase 1 Terminated

Indolent Lymphoma

NCT01660451 2024-07-17

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Phase 2 Completed

227 enrolled 25 charts

Lymphoma, Non-Hodgkin

NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase 1 Terminated

8 enrolled 17 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05387616 2024-03-12

Alternative-C

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04263584 2024-01-05

COPA-R-CHOP

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT04803123 2023-12-21

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Phase EARLY_PHASE1 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Phase 1/2 Terminated

31 enrolled 17 charts

CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT02369016 2023-11-18

CHRONOS-2

Phase 3 Completed

25 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT04156828 2023-06-29

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02342665 2023-01-20

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

NCT03877055 2022-12-14

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Phase 1/2 Completed

8 enrolled 7 charts

Lymphoma, Mantle-Cell

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

1 enrolled 6 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03498430 2021-05-19

Copanlisib Chinese PK Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT02253420 2020-12-14

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Phase 1 Withdrawn

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT02391116 2019-01-04

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Completed

67 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

NCT02455297 2017-10-02

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase 2 Terminated

Lymphoma, Mantle-Cell

NCT02155582 2017-06-16

Copanlisib Pharmacodynamic Study

Phase 1 Completed

Lymphoma, Non-Hodgkin